Kaviaar schreef op 1 februari 2022 11:25:
Celyad Oncology Announces February 2022 Conference Schedule
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022:
Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022 Dates: Monday, February 14 to Friday, February 18, 2022 Presentation: February 18, 8 a.m. ET / 2 p.m. CET
Presenter: Filippo Petti, CEO
Webcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit
www.celyad.com.